CIRM Funded Clinical Trials

A Phase I/IIa Dose Escalation Safety Study of AST-OPC1 in Patients with Cervical Sensorimotor Complete Spinal Cord Injury


Jane Lebkowski
Disease Area: 
Investigator:
CIRM Grant:
Award Value:
$14,323,318
Trial Stage: 
Phase 1/2
Trial Status: 
Recruiting
Targeted Enrollment:
35
ClinicalTrials.gov ID:
Details: 

Up to 12,000 Americans suffer a spinal cord injury each year. Leads to a high level of permanent disability and decreased life expectancy. Currently no approved therapies.

Design: 

Open label, single arm, dose escalation safety study.

Goal: 

Safety. Dosing. Efficacy - motor improvement.

Status: 

Ongoing. Favorable safety profile to date, interim analysis confirms safety. Improvement in upper extremity motor function through 9 months post-treatment in cohort 2.